title: Danazol in the treatment of myelodysplastic syndromes.
abstract: 20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.
authors.affiliation: Arizona Cancer Center, Tucson.
authors.forename: A C
authors.initials: AC
authors.lastname: Buzaid
authors.forename: H S
authors.initials: HS
authors.lastname: Garewal
authors.forename: S M
authors.initials: SM
authors.lastname: Lippman
authors.forename: B G
authors.initials: BG
authors.lastname: Durie
authors.forename: S B
authors.initials: SB
authors.lastname: Katakkar
authors.forename: B R
authors.initials: BR
authors.lastname: Greenberg
mesh_terms: D002986:Clinical Trials as Topic; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*
chemical_list: D011245:Pregnadienes; D003613:Danazol